The Use of Experimental Design Methods in the Development of a High Concentration Lyophilized Formulation for a Humanized Monoclonal Antibody

2003 ◽  
Vol 2 (5) ◽  
pp. 57-63
Author(s):  
Supriya Gupta ◽  
Aleni-Flores Nate ◽  
Elizabet Kaisheva
Keyword(s):  
Monoclonal Antibody ◽  
Experimental Design ◽  
Design Methods ◽  
High Concentration ◽  
Lyophilized Formulation ◽  
Humanized Monoclonal Antibody

scholarly journals Clearance Kinetics and External Dosimetry of 131I-Labeled Murine and Humanized Monoclonal Antibody A33 in Patients with Colon Cancer: Radiation Safety Implications

2009 ◽  
Vol 96 (5) ◽  
pp. 550-557 ◽  
Author(s):  
Lawrence T. Dauer ◽  
Daniel C. Boylan ◽  
Matthew J. Williamson ◽  
Jean St. Germain ◽  
Steven M. Larson
Keyword(s):  
Monoclonal Antibody ◽  
Colon Cancer ◽  
Radiation Safety ◽  
Humanized Monoclonal Antibody ◽  
Clearance Kinetics

scholarly journals Organic Nanocarriers for Bevacizumab Delivery: An Overview of Development, Characterization and Applications

Molecules ◽  
2021 ◽  
Vol 26 (14) ◽  
pp. 4127
Author(s):  
Aline de Cristo Soares Alves ◽  
Franciele Aline Bruinsmann ◽  
Silvia Stanisçuaski Guterres ◽  
Adriana Raffin Pohlmann
Keyword(s):  
Monoclonal Antibody ◽  
Physicochemical Characterization ◽  
Vascular Endothelial ◽  
Organic Nanoparticles ◽  
Humanized Monoclonal Antibody ◽  
Angiogenesis Process ◽  
Endothelial Growth Factor ◽  
Drug Pharmacokinetics

Bevacizumab (BCZ) is a recombinant humanized monoclonal antibody against the vascular endothelial growth factor, which is involved in the angiogenesis process. Pathologic angiogenesis is observed in several diseases including ophthalmic disorders and cancer. The multiple administrations of BCZ can cause adverse effects. In this way, the development of controlled release systems for BCZ delivery can promote the modification of drug pharmacokinetics and, consequently, decrease the dose, toxicity, and cost due to improved efficacy. This review highlights BCZ formulated in organic nanoparticles providing an overview of the physicochemical characterization and in vitro and in vivo biological evaluations. Moreover, the main advantages and limitations of the different approaches are discussed. Despite difficulties in working with antibodies, those nanocarriers provided advantages in BCZ protection against degradation guaranteeing bioactivity maintenance.

scholarly journals Reduction of Respiratory Syncytial Virus (RSV) in Tracheal Aspirates in Intubated Infants by Use of Humanized Monoclonal Antibody to RSV F Protein

1998 ◽  
Vol 178 (6) ◽  
pp. 1555-1561 ◽  
Author(s):  
Richard Malley ◽  
John DeVincenzo ◽  
Octavio Ramilo ◽  
Penelope H. Dennehy ◽  
H. Cody Meissner ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Respiratory Syncytial Virus ◽  
F Protein ◽  
Humanized Monoclonal Antibody ◽  
Syncytial Virus ◽  
Tracheal Aspirates

scholarly journals A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes

2011 ◽  
Vol 162 (8) ◽  
pp. 1855-1870 ◽  
Author(s):  
EG Stefanich ◽  
DM Danilenko ◽  
H Wang ◽  
S O'Byrne ◽  
R Erickson ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
T Lymphocytes ◽  
Humanized Monoclonal Antibody ◽  
Antibody Targeting

scholarly journals Synovial tissue responses following treatment of rheumatoid arthritis with the humanized monoclonal antibody CAMPATH-1H

1996 ◽  
Vol 39 (1) ◽  
pp. 181-182 ◽  
Author(s):  
Enrique R. Soriano ◽  
Jonathan Dixey ◽  
Nicolas D. Hall ◽  
Joan Davies ◽  
Peter J. Maddison
Keyword(s):  
Rheumatoid Arthritis ◽  
Monoclonal Antibody ◽  
Synovial Tissue ◽  
Humanized Monoclonal Antibody ◽  
Tissue Responses
Sign in / Sign up

Export Citation Format

Share Document